Audentes reports interim Phase I/II data for XLMTM candidate

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) reported interim data from the first cohort of the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy, a rare monogenic disease characterized by extreme muscle weakness, respiratory failure and early death.

In a

Read the full 422 word article

User Sign In